Biobank Pancreas Carcinoma: Storing Blood for Analysis of DNA and Protein of Patients With Pancreas Cancer
Information source: Maastricht Radiation Oncology
Information obtained from ClinicalTrials.gov on October 19, 2009
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Pancreas Cancer
Phase: N/A
Status: Recruiting
Sponsored by: Maastricht Radiation Oncology Official(s) and/or principal investigator(s):
Dirk De Ruysscher, PHD, Principal Investigator, Affiliation: CCMO
Overall contact:
Philippe Lambin, Prof PHD, Phone: +31 (0) 88 44 55 666, Email: philippe.lambin@maastro.nl
Summary
The purpose of this study is to determine, by means of DNA and protein analysis, the
relationship between DNA and protein profiles and a number of endpoints which are important
for the patient such as overall survival and side effects.
Clinical Details
Official title: Storing Blood for Analysis of DNA and Protein of Patients With Pancreas Cancer in MAASTRO Clinic
Study design: Cohort, Prospective
Detailed description:
It has already been known for a long time that cancer is a genetic disorder and that the
development of the illness is a very complex interaction between genetic and surrounding
factors. Also the response on therapy and the development and seriousness of side effects is
stipulated by this complicated collaboration of genetic and surrounding factors. Moreover it
is not only the DNA that plays an important role but also the systems of control at protein
level. At this moment a lot of questions remain to be answered because up till now the
studies were of rather restricted statistic strength with frequently inconsistent dates and
moreover retrospective. Major retrospective studies are necessary to distinguish the
relationship between DNA/protein patterns and clinical relevant endpoints like prognosis and
toxicity in which an as broad as possible patient group is being monitored. For this reason
we want to draw blood in MAASTRO clinic of all patients with pancreas cancer and store it
encrypted so that we can perform DNA and protein analyses in future and to correlate the
results with survival and toxicity of the treatment.
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Pancreas cancer
Exclusion Criteria:
- Not able to comply with follow-up
Locations and Contacts
Philippe Lambin, Prof PHD, Phone: +31 (0) 88 44 55 666, Email: philippe.lambin@maastro.nl
Maastricht Radiation Oncology, HEERLEN, Limburg 6419 PC, Netherlands; Recruiting
Dirk De Ruysscher, PHD, Phone: +31 (0) 88 44 55 666, Email: dirk.deruysscher@maastro.nl
Danielle De Haas, Phone: +31 (0) 88 44 55 666, Email: danielle.dehaas@maastro.nl
Additional Information
Starting date: October 2003
Ending date: October 2025
Last updated: September 2, 2009
|
